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Spasticite´ (II) / Revue d’E´pide´miologie et deDiscussion.– SEF is a major cause of disability for stroke patients, impairing
their daily living activities, social participation and quality of life. When this
deformity is primarily due to muscle overactivity, various focal treatments
including selective neurotomy can be proposed together with the rehabilitation
program. This neurosurgical procedure consists of a partial and selective section
of the motor nerve branches that innervate spastic muscles. For a low cost, it can
permanently reduce muscle overactivity. However, its effectiveness had only
been suggested through uncontrolled case series studies [1], mainly focussing
on body structures and functions.
The present study demonstrates with a high level of scientific evidence that
tibial nerve neurotomy is an efficient treatment of SEF, reducing impairments of
chronic stroke patients. Future studies should still be conducted in order to
confirm the long-term efficacy of this treatment following the International
Classification of Functioning, Disability and Health (ICF).
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Objective.– To study the interest of the use of an anesthetic cream in prevention of
the pain during the injections of botulinum toxin at the child and the teenager.
Method.– The evaluation is realized in two populations of cerebral palsy
children and teenagers. A population receives the application of anesthetic
cream before the injections. Other population is injected without anesthetic
cream. The pain is estimated by a score EVA or a scal of CHEOPS according to
the capacities of the patient. The ‘‘reactivity’’ is appreciated in ‘‘important,
average, low, no’’.
In 2011, we presented a preliminary study but series, too small did not allow a
statistical study.
Results.– We have 193 medical records. The clinical forms were variable
(classification GMFCS). Ninety-seven were evaluated their pain on an EVA, 96
other, are estimated by the CHEOPS. Ninety-six had received anesthetic cream,
97 were injected without. Two populations were homogeneous. The average of
EVA is 2,9 with the cream 2 without. The average of CHEOPS is 7 with the
cream, 7,2 without. We also analyze the results according to the age, to the
number of muscles, concerned limbs or an adjuvating treatment.
Discussion.– Other factors such as the waiting time before injection is probably
involved in the patient’s anxiety.
The passage of the skin seems to us also less painful since we use the electric
stimulation, the needles being finer.
It is more often to the injection of the product than to the passage of the skin that
the child reacts.
Conclusion.– This work does not justify the usefulness of applying an anesthetic
cream prior to injections of botulinum toxin in cerebral palsy children and
adolescents to decrease the pain induced.
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Introduction.– Intrathecal baclofen is known as an effective treatment of
muscular hypertonia in chronic stages of vascular or traumatic brain damaged
subjects [1]. Its interest in early management is supported by its effects on
neurovegetative crisis [2].
Materials and methods.– A 61-year-old female patient in persistent vegetative-
nervous state two months after a bilateral anterior cerebral artery stroke,
presented with spastic tetraplegia and equine retracted feet despite an optimal
antispastic treatment (oral treatment and botulinum toxin injections).
Considering a global muscle hypertonia with a mean score (MAS) of 3.8 on
inferior limbs and 3 on superior limbs, and after positive intrathecal baclofen
test, pump implantation was decided on day 90 after stroke.
Results.– An improvement of hypertonia of 2 points (MAS) on inferior limbs
and of 1.4 on superior limbs facilitating the patient’s nursing and bed
positioning, as well as an improvement of WHIM of 21 points were noted one
week after treatment. No complication was reported.
Discussion.– A diffuse muscle hypertonia with secondary neuro-orthopedic
complications can appear in early stages after a severe brain damage. Our case
emphasizes the importance of screening and early management of those muscle
tonus troubles, with particular interest in early intrathecal baclofen treatment.
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Objective.– To describe the adverse events (AE) occurring after intrathecal
baclofen (ITB) pump placement.
Patients and methods.– We prospectively collected all the AE occurring in
patients receiving ITB via a pump, from the rehabilitation setting of R.-Poincaré
Hospital during 2010.
Results.– 158 patients were enrolled, mean age 46 years and 65% male. 128
patients were former implanted (FI) and 30 had a pump placement during 2010:
20 new-implanted (NI) and 10 replacements (R). Most of patients were SCI
patients (44 paraplegic and 23 tetraplegic) and MS patients (45). 18% of the
patients had one or more complications (38 complications). For a total follow-
up of 1665 months, there were 0,023 complications per pump-month.
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in 29% and postoperative complications in 55%. 63% of NI or R patients had
adverse events vs 7% of FI patients.
Discussion.– The incidence of AE in our study was 0,27 complications per
pump-year. This was more that Bensmail et al. [1] observed. They described
0,11 complications per pump-year in 44 MS patients in a 12-years follow-up,
but only equipment dysfunctions were collected. Tassëel-Ponche et al. [2]
reported 72% of AE in a population of 25 cerebral palsy in a 10-years follow-up,
with 0,07 serious complications per pump-year (required an hospitalization), vs.
0,014 in our study.
Conclusion.– This prospective study collected AE occurring after ITB pump
placement in a large population. Procedures should be created to reduce the
incidence of these AE.References
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